SCHEMBL6925564

SCHEMBL6925564

COc1ccc(NC(c2ccc(Cl)cc2CN2CCC[C@H]2C(N)=O)C(F)(F)F)cc1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.45
SCN3A Q9NY46 1/20 0.41
MAOB P27338 2/20 0.40
MAOA P21397 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
RECQL P46063 1/20 0.40
EP300 Q09472 1/20 0.40
CREBBP Q92793 1/20 0.40
HCRTR1 O43613 2/20 0.39
HCRTR2 O43614 2/20 0.39
DDR1 Q08345 3/20 0.39
SCN9A Q15858 1/20 0.39
CCR1 P32246 1/20 0.38
MDM2 Q00987 1/20 0.38
SPHK1 Q9NYA1 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6925575 0.87 EGFR (0.45) EGFRSCN3AMAOBMAOATSHR
SCHEMBL6923417 0.82 EGFR (0.45) EGFRSCN3AMAOBMAOATSHR
SCHEMBL6924610 0.77 ALDH1A1 (0.61) EP300CREBBPALDH1A1
SCHEMBL7379279 0.76 CNR1 (0.35) EP300CREBBPHCRTR1HCRTR2DDR1
SCHEMBL7377904 0.76 MDM2 (0.35) EP300CREBBPDDR1MDM2KDM4E
SCHEMBL6926419 0.76 MEN1 (0.48) TSHRMDM2KDM4EALDH1A1
SCHEMBL6926479 0.76 F2 (0.60) EP300CREBBPALDH1A1
SCHEMBL30708212 0.75 EGFR (0.54) EGFRSCN3ATSHRMAPK1RECQL
SCHEMBL6923255 0.73 HTR2C (0.46) DDR1SCN9AMDM2KDM4EALDH1A1
SCHEMBL6923372 0.68 ALDH1A1 (0.53) TSHRMAPK1RECQLDDR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515011-B2 Anticoagulants MERCK & CO., INC. 2003-02-04 US disclosed
US-20020119992-A1 Thrombin inhibitors MERCK & CO., INC. 2002-08-29 US disclosed
WO-2002050056-A1 BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119992-A1 Thrombin inhibitors SERPINC1, F2, TFPI EGFR 2856/4885SCN3A 1584/4885MAOB 2230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.